| [1] |
Jung SJ, Woo SM, Park HK, et al. Patterns of initial disease recurrence after resection of biliary tract cancer[J]. Oncology, 2012, 83(2): 83-90.
|
| [2] |
陶连元，何小东，高飞, 等. 肝外胆管癌的临床病理与预后分析[J]. 肝胆外科杂志, 2011, 19(4): 251-253.
|
| [3] |
Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase Ⅲ multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma[J]. Cancer, 2002, 95(8): 1685-1695.
|
| [4] |
Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial[J]. JAMA, 2012, 308(2): 147-156.
|
| [5] |
Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis[J]. J Clin Oncol, 2012, 30(16): 1934-1940.
|
| [6] |
Hoehn RS, Wima K, Ertel AE, et al. Adjuvant chemotherapy and radiation therapy is associated with improved survival for patients with extrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2015, 22 Suppl 3: S1133-S1139.
|
| [7] |
McNamara MG, Walter T, Horgan AM, et al. Outcome of adjuvant therapy in biliary tract cancers[J]. Am J Clin Oncol, 2015, 38(4): 382-387.
|
| [8] |
Yang H, Zhou J, Wei X, et al. Survival outcomes and progonostic factors of extrahepatic cholangiocarcinoma patients following surgical resection: adjuvant therapy is a favorable prognostic factor[J]. Mol Clin Oncol, 2014, 2(6): 1069-1075.
|
| [9] |
Mizuno T, Ebata T, Yokoyama Y, et al. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis[J]. Surg Today, 2017, 47(2): 182-192.
|
| [10] |
NCCN Clinical Practice Guidelines in Oncology-Hepatobiliary Cancers, Version 1.2017[DB/OL].
URL
|
| [11] |
国际肝胆胰学会中国分会，中华医学会外科学分会肝脏外科学组. 胆管癌诊断与治疗——外科专家共识[J]. 临床肝胆病杂志, 2015, 31(1): 12-16.
|
| [12] |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281.
|
| [13] |
Kobayashi S, Nagano H, Sakai D, et al. Phase Ⅰ study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study[J]. Cancer Chemother Pharmacol, 2014, 74(4): 699-709.
|
| [14] |
Kainuma O, Miura F, Furukawa D, et al. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer[J]. J Hepatobiliary Pancreat Sci, 2015, 22(11): 789-794.
|
| [15] |
Yamanaka K, Hatano E, Kanai M, et al. A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer[J]. Int J Clin Oncol, 2014, 19(3): 485-489.
|
| [16] |
Stein A, Arnold D, Bridgewater J, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase Ⅲ trial[J]. BMC Cancer, 2015, 15: 564.
|
| [17] |
Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials[J]. Br J Cancer, 2007, 96(6): 896-902.
|
| [18] |
Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study[J]. J Clin Oncol, 2017, 35(15_suppl): 4006.
|
| [19] |
Wirasorn K, Ngamprasertchai T, Khuntikeo N, et al. Adjuvant chemotherapy in resectable cholangiocarcinoma patients[J]. J Gastroenterol Hepatol, 2013, 28(12): 1885-1891.
|
| [20] |
Gwak HK, Kim WC, Kim HJ, et al. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2010, 78(1): 194-198.
|
| [21] |
Kim S, Kim SW, Bang YJ, et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer[J]. Int J Radiat Oncol Biol Phys, 2002, 54(2): 414-419.
|
| [22] |
Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2009, 73(1): 148-153.
|
| [23] |
Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct[J]. Int J Radiat Oncol Biol Phys, 2007, 68(1): 178-182.
|
| [24] |
Dover LL, Oster RA, McDonald AM, et al. Impact of adjuvant chemoradiation on survival in patients with resectable cholan-giocarcinoma[J]. HPB (Oxford), 2016, 18(10): 843-850.
|
| [25] |
Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase Ⅱ intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. J Clin Oncol, 2015, 33(24): 2617-2622.
|